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Analysis of the Venoms of Four Subspecies of the Western Rattlesnake 
(Crotalus oreganus) 
Natalie Crouch  
(Dr. Stephen P. Mackessy)  
Abstract  
 Recently, the benefits venom can have in the discovery and development of different 
medications to assist in treating a variety of diverse human diseases have been areas of research. 
In order to develop a better understanding of how to evaluate venoms for potential use as 
therapeutics, one needs to look at the fundamental composition of venom samples. This project 
aims at discovering and analyzing the basic components from the venom of four different 
subspecies of the Western Rattlesnake complex (Crotalus oreganus and C. viridis ). Venom 
samples collected will be subjected to size exclusion chromatography to separate proteins of 
different sizes in the venom. After fractionation of venoms, the following assays are conducted 
on individual fractions to locate specific activities of enzymatic venom proteins: 
metalloproteinase activity, kallikrein-like and thrombin-like serine proteinase activities, 
phospholipase A2 activity, phosphodiesterase activity and L-amino acid oxidase activity. Gel 
electrophoresis will evaluate the complexity of each fractionated protein peak, and samples will 
be dialyzed, removing salts, and then lyophilized, allowing for stable storage for later 
experiments. These tests will compare the basic biochemistry of the samples of venoms from the 
different subspecies to help expand knowledge on venom chemistry differences between closely 
related subspecies of rattlesnakes. Snakes use their venoms primarily to obtain food, and results 
will allow for further evaluation of how their differing venom compositions relate to specific 
aspects of their ecology, such as use of divergent habitats, potential risks of different predators 
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and effects on various prey species utilized. These subspecies are separated geographically, and 
rattlesnakes in general expanded their ranges from south/west to north/central regions, so this 
project will also reflect how their venoms have evolved over time, as well as revealing those 
components that have remained static and are shared among all subspecies analyzed. Because 
envenomation symptoms will vary due to venom composition, these results will also help inform 
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 Venom composition can vary based on the snakes’ age, sex, and geographic distribution. 
The age of the snake plays a large role in the composition of its venom. As neonates, many 
rattlesnakes consume lizards and small rodents, but as adults they tend to consume larger 
rodents, perhaps necessitating a different venom composition as they age. Juvenile rattlesnake 
venom is more toxic than adult venoms, while adult venoms often contain much higher levels of 
metalloproteinases than neonates (Mackessy, 1988). Neurotoxic phospholipases A2 of juvenile 
rattlesnakes have more lethal venoms than adult rattlesnakes, as this activity is shown to decrease 
with age, based on a study of the Central American Rattlesnake Crotalus simus (Gutiérrez et al., 
1991). Adult venom variation between species are the result of natural selection and evolution 
acting upon a snake species, resulting in random mutations that lead to greater adaptation to 
specific conditions and prey utilized in an area. Other factors that have caused the population of 
snake species to separate are natural changes in the landscape, including deep time events, such 
as tectonic plate shifting to create mountains, and more recent, sudden events, most importantly 
human expansion leading to loss of habitat. Adaptations to these differential forces cause 
populations to change over time until sufficient genetic differentiation results in the formation of 
genetically distinct populations (subspecies) or even so differentiated as to be categorized as 
different species. The taxonomic status of certain individual groups are continuously debated in 
the scientific community as to whether or not to be considered subspecies of the same species, or 
as distinct species (e.g., Davis et al., 2016).   
Review of Literature 
There are nearly 3,900 species of snakes known on Earth (Uetz et al., 2020). Snakes 
occur on most of landmasses as well as many of the oceans and freshwater environments. 
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Individual groups are separated into different species when they are no longer able to breed due 
to genetic isolation or if DNA-based studies reveal significant genetic differences. Subspecies 
are a distinct subpopulation of a species, and they differ from species in that a subspecies cannot 
exist without the species but can only be expressed in relation to the species. At least two 
subspecies are needed in order to designate subspecies of a species. Subspecies were created due 
to recognition of population variants in animals that can still interbreed. Though subspecies have 
similar genetics, the point of determination between normal variation in the population and 
genetically different subspecies determination can be hard to distinguish. Due to this 
determination being a gray area, many scientists have different beliefs on whether or not a group 
of individuals should be considered a subspecies or not, or if the concept of subspecies is even 
valid. 
Venomous snakes have a complex system of glandular secretions that comprise venom, 
which is used primarily as a trophic adaptation to obtain food, and secondarily to help defend 
against potential threats. Venom differs from poison because venom has to be injected, whereas 
poison needs to be consumed. For example, injection occurs through a snake’s fangs, whereas 
poison is more effective by swallowing a toxic animal, such as a Taricha newt. The venom 
contains a variety of proteins, peptides, carbohydrates, neurotransmitters, amines and other 
substances that are produced within specific cephalic glands. The venom proteins are synthesized 
via secretory cells that comprise the bulk of the venom gland. They are synthesized in the rough 
endoplasmic reticulum, passed through the Golgi apparatus and then transported out of the cell 
into the gland via granules (Mackessy, 1991). Within a single specimen, there could be up to 100 
proteins (including isoforms). Venom is composed of a plethora of enzymes that vary between 
species and even somewhat between individuals. A rough estimate puts the two families of 
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Elapidae and Viperidae containing around 19,000-25,000 individual proteins in these venoms 
(Laustsen, 2018). Snakes have been shown to have control of the release of venom during a bite. 
Both venom glands, on the right and left, can be independently controlled to release the correct 
amount of venom for the situation the snake is in (Mackessy, 1988). This allows for snakes to 
save venom if not all is needed to take down their prey.  Enzymes experimented on extensively 
tend to be ones that cause major pathology within humans or other species. There are around half 
a dozen common enzyme activity tests that can be performed for compounds that are found in 
most rattlesnake venom that cause humans pathological problems. Knowing more about these 
enzymes will aid in learning about the symptoms they cause and how to counteract the enzyme 
in a medical setting to reduce symptoms and help the individual with eliminating the toxins. 
Snake venoms may hold the key to many medical advancements that have already been 
discovered and potentially many more in the near future. Almost 40 years ago, the first 
successful medication was made from isolating a toxin found in Bothrops jararaca venom (Koh 
and Kini, 2021). Since then, other toxins within venoms have been carefully studied to create 
new medicines. Antiplatelet and anticoagulant agents are present in many venoms of 
rattlesnakes. Both possess qualities to help treat heart attacks, pulmonary embolisms and strokes. 
Heart attacks are one of the top killers of people in the world. Utilizing metalloproteinase 
enzymes, serine proteases enzymes or other enzymes could be paired to other medicines, 
including anti-inflammatories, to help break up the clot before it is able to cause problems in the 
human body. Though more research is needed in order to perfect the concentration and 
application, it opens up room for amazing medical advantages in the future.  
In addition to breaking up clots in the body, venom proteins show promising solutions for 
helping fight cancer. In total, 18,094,716 new cases of cancer, excluding non-melanoma skin 
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cancer, arose in the world in 2020, with 1,970,287 of those cases being from North America 
(Global Cancer Observatory, 2020). Venom enzymes, or more specifically disintegrins, in the 
venom show the possibility of inhibiting new blood vessels from being made to supply the tumor 
cells. This research could stop the growth of tumors due to them being cut off from the body's 
blood supply (Koh and Klnl, 2021). L-amino acid oxidase in venom could also be used as a 
cancer treatment causing cancer cells to undergo apoptosis/necroptosis, cell death, due to 
intrinsic or extrinsic pathways that may be signaled because of hydrogen peroxide byproduct, a 
reactive oxygen species (Mukherjee, 2015). A peptide, exendin-4, was isolated from the venom 
of the Gila Monster (Heloderma suspectum), a venomous lizard, and is used to help treat type-2 
diabetes. This peptide targets the body's natural insulin-producing pathways and can activate it 
without glucose. This has resulted in the synthesis of Byetta, a medicine currently used to treat 
type-2 diabetes. These examples just scratch the surface of what has already been discovered and 
what potential venom holds for future discoveries.  
Wollberg et al. (1988) found that myotoxins have a direct effect on contractibility and the 
body’s continuous movements by affecting the channels that act without our muscular system. 
The mulgotoxins lead to decrease contractile response when the nerve receptors stimulate the 
muscle. This can be applied to smooth, muscular, or cardiac muscle tissues. Reduced 
contractility of these cardiac muscles can lead to a reduced ventricular ejection and lower blood 
pressure; however, that also means less oxygenated blood is leaving the heart and getting to the 
body. Dias et al. (2012) performed a study on dogs in Brazil to examine the hemodynamic 
responses to Bothrops alternatus venom and to assess the extent to which they were related to 
metabolic alterations, cardiac tissue damage, and venom kinetics. The results showed that there 
was no significant change in blood gas, but there was an increase in plasma lactate 
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dehydrogenase in the lower venom doses. After four hours, the venom was still detectable but in 
very low quantities, and the injection showed an increase in the subject's hypotension along with 
a few other metabolism alterations. This information showed that small doses could alter the 
body's systems and circulate within the body without hurting or killing the animal that was 
injected. These experiments allowed for the medical researchers to see that the venom, in small 
doses, can be safely used without killing the patient. Lastly, Mangiafico et al. (2012) performed a 
similar trial later that year on dogs and rats. Their experiments consisted of administering an 
experimental medicine that had a low dose of snake venom present, and this was given to the 
animals to see the effects the medication would have on the blood pressure. The resulting drug 
was named LCZ696, which is a mixture of cardiovascular medications and snake venom 
proteins. LCZ696 is the first to show that drugs mixed with a low dose of venom can still be safe 
and help lower extremely high blood pressure. More trials are needed to perfect this medicine so 
that it can be added to medical practice to help quickly and safely reduce the blood pressure of 
patients, allowing for less stress being placed on the heart, arteries, and veins.  
The discovery of anti-venom helped to decrease the death rate from envenomation. Anti-
venom works by neutralizing the components of an animal's venom. The ability to make anti-
venom relies on the detailed knowledge of the biological makeup of the snake's venom. In 
certain regions of the world, envenomation from snakes causes high death rates among the 
people. In one example of the efficacy of antivenom, bites by the South America Rattlesnake 
(Crotalus durissus terrificus), a member of the snake family Viperidae, showed a 71.5% 
decrease in death rate after the introduction of anti-venom for this snake (Baum et. al. 2019). 
Research is still under way to discover more novel antivenoms using different approaches 
including, but not limited to, recombinant antibody formats and toxin-neutralizing proteins 
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isolated from animals. However, currently the most effective and developed antivenoms are in 
serum form (Laustsen, 2018). Anti-venoms are made by inoculating experimental animals, most 
often horses, sheep or goats, with increasing doses of venoms and then harvesting polyclonal 
antibodies from their serum. These animals produce these antibodies due to being exposed to 
sublethal doses of a certain type of venom from one species (monovalent antivenom) or multiple 
snake species (polyvalent antivenom) (Silva and Isbister, 2020). After reaching a high level of 
antibody titer, the antibodies are purified and used as intact antibodies (IgG) or they are 
subjected to proteolytic cleavage to produce Fab/Fab2 fragments that can then be given to a 
patient intravenously (Slagboom et al., 2017).  
 The snakes used in the present study were Crotalus species from the family Viperidae, 
and they represent species/subspecies of the Western Rattlesnake complex (Figure 1). Viperidae 
are found mainly in Africa, Asia, and Europe. Viperidae contains around 53 species of 
rattlesnakes (Westerm et al., 2008). The subfamily Crotalinae is mainly found in Asia and in the 
Americas. They have a pair of heat-sensitive organs on the anterior part of their head that allow 
them to locate and hunt warm-blooded creatures at night. They also all have a pair of fangs, 
which are anteriorly placed in the maxilla of the snake. They are able to rotate their fangs, 
folding them against the roof of the mouth when they are not in use. Crotaline snakes tend to 
hibernate during winter months and often bask in the sun during the active season. Oftentimes, 
snakes are seen to den in large groups and have been observed to travel very long distances to 
locate a denning site that fits their needs. This natural tendency to hibernate and form dens has 
been shown to be due to juveniles being able instinctively to follow other snake’s chemical trails 
to find den sites without ever having done it before and without parental guidance (Gienger and 
Beck, 2011). Adults also show specificity to certain sites and some den sites have over a 90% 
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return rate of the same individuals the next year, even when individuals were quite far away 
(Hirth, 1966).  After those long winter months, they tend to bask, allowing the sun to help them 
warm up in order to reactivate their physiological systems.  
Due to a reduction in habitat, rattlesnakes are starting to experience changes to their 
health and reproduction cycles that are outside their normal range; Glissmeyer (1951) showed 
this phenomenon long ago. Their best estimation is that the reduced number of eggs produced, 
leading to population declines, results from habitat loss (Glissmeyer, 1951). 
The composition of venom is the measure of the chemical makeup of the venom obtained 
from a snake. It often varies based on the genus and species of the snake. However, many of the 
more significant parts of the venom are shared between species. Most venoms of Western 
rattlesnakes have significant amounts of metalloproteinases, serine proteinases, and PLA2 
(Mackessy, 2010). The amount of each enzyme found in the venom sample can help to identify 
species. Some species will have higher levels of metalloproteinases, which produce severe tissue 
damage and necrosis; however, species with venoms that are higher in metalloproteinase activity 
tend to be less toxic (Mackessy, 2010). The relative amounts of toxins also may change with age, 
even within one species (Mackessy, 1988). For example, Durban et al. (2013) showed that there 
is a gradual reduction, as the snake gets older, of the expression of serine proteinases and PLA2, 
causing the venoms of the neonate snakes to be of higher toxicity than venoms of adults of the 





Figure 1. Distribution of the Western Rattlesnake (Crotalus oreganus and C. viridis) and the 
Mohave Rattlesnake (C. scutulatus). The four taxa used in this study are indicated by the red 
bracket. (Figure is from Schield et al., 2019). 
Distribution of snakes used in this study 
Crotalus oreganus helleri, the Southern Pacific Rattlesnake, lives mostly in southwestern 
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California to northwestern Mexico (Figure 2). Their diet consists largely of lizards as juveniles, 
including small mammals and birds in adulthood as their venom composition changes with age 
(Mackessy, 1988; Smith and Mackessy, 2016). The change in diet may be associated with 
ontogenetic changes in venom composition, and PLA2 activity decreases while metalloproteinase 
activity increases in adults as compared to juveniles (Mackessy 1988). Adult Southern Pacific 
Rattlesnakes show increased proteolytic venom compared to juveniles (Mackessy, 1988; Gren et. 
al., 2016). The Southern Pacific Rattlesnake tends to be darker brown, gray or black in color.  
 
 
Figure 2. Crotalus oreganus helleri (Southern Pacific Rattlesnake) from Los Angeles; 
reproduced from Dr. Stephen Mackessy website at the University of Northern Colorado (with 
permission).   
 
 Crotalus oreganus oreganus, the Northern Pacific Rattlesnake (Figure 3), inhabits mostly 
the Western United States and feeds on small rodents, reptiles and birds based on their age. The 
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color is extremely variable with light/dark brown/ grey or olive brown. They range in length up 
to 58 inches (Uetz et al., 2020).  
 
Figure 3. Crotalus oreganus oreganus (Northern Pacific Rattlesnake). Photo by S.S. Sweet 
(1983); reproduced from Dr. Stephen Mackessy website at the University of Northern Colorado 
(with permission).  
 
Crotalus oreganus lutosus, the Great Basin Rattlesnake (Figure 4), is found mostly in 
western United States in the Great Basin desert, and they are typically found in more arid 
environments. They feed primarily on lizards and rodents and have a lighter brown or gray color 




Figure 4. Crotalus oreganus lutosus (Great Basin Rattlesnake); reproduced from Dr. Stephen 
Mackessy website at the University of Northern Colorado (with permission). 
 
Crotalus oreganus cerberus- Arizona Black Rattlesnake  
 Crotalus oreganus cerberus, the Arizona Black Rattlesnake, has a darker pattern of either 
black, gray, olive or brown with light blotches throughout its body; older males tend to become 





Figure 5. Crotalus oreganus cerberus (Arizona Black Rattlesnake); reproduced from Dr. Stephen 
Mackessy website at the University of Northern Colorado (with permission). 
Assay background  
Metalloproteinase assays measure the amount of metalloproteinases in the venom. 
Metalloproteinases break down collagen and other proteins in the body when injected from a 
snake bite, found as connective tissues in blood vessels, organ structures, basement membranes 
of epithelial tissues and extracellular spaces of the body of vertebrates. These venom proteins 
cause major structural damage, while other venom components inhibit coagulant factors or 
platelets, neutralizing clotting proteins and causing the bite site to be unable to clot and stop the 
bleeding. This can cause bleeding at the site of the bite as well as systemic bleeding if medical 
attention is not received immediately. Metalloproteinases also disrupt vascular endothelium that 
19 
 
is found on the inner lining of veins, capillaries, and arteries, allowing blood to escape through 
these passages as a result of damage to the walls. Due to this anticoagulation and vascular 
endothelium, thinning the metalloproteinases helps to spread other proteinase components into 
the circulatory system of the victim (Maruyama, 2013). Most rattlesnakes venoms contain high 
metalloproteinase activity and bites can lead to severe bleeding and potential death if left 
untreated.  
Serine proteases (both thrombin-like and kallikrein-like) aid metalloproteinases in the 
disruption of the vascular system and the disruption of the body’s defense to clot or repair blood 
vessels. L-amino acid oxidase is responsible for many different side effects from snake venom 
bites and is very common in venomous snakes. The enzyme is a homodimer consisting of three 
domains: substrate-binding domain, FAD-binding domain, and helical domain (Doley and Kini, 
2009). The L-amino acid oxidase gives rise to the yellow color of venom due to the presence of 
the cofactor flavin adenine dinucleotype (FAD). The enzyme’s activity gives rise to peroxide 
radicals that are able to damage various structures, including DNA. Though some biological 
effects are unclear, and it is uncertain exactly how L-amino acid oxidase affects humans, it is 
believed to activate inflammation and promote a pro-apoptosis factor in human cells, primarily 
as a result of generation of peroxide radicals (Watt et al., 2004).  
Phospholipase A2 exists in significant amounts in many snake venoms, especially in 
younger snakes, and may act as a neurotoxin. They have been found to be monomers but can 
interact with other phospholipase A2 or other proteins. Isoforms of phospholipase A𝐴2have been 
shown to bind to the presynaptic site of a neuromuscular junction and cause acetylcholine to not 
be released as readily. This decrease of acetylcholine can lead to flaccid paralysis of the muscles 
and shut down of neurotransmission (Doley and Kini, 2009). Other non-neurotoxic 
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phospholipase A2 can enter the circulatory system and cause heart problems, including 
hypotension. It also may interact with other enzymes in the venom to inhibit platelet formation, 
promote anticoagulation and can cause inflammation at the site of the injection, as well as 
systemically (Gimenes et al. 2014).  
Phosphodiesterase activity can disrupt cell signaling in the body as well as act to 
hydrolyze both RNA and DNA. Phosphodiesterase works best under somewhat basic pH and 
catalyzes the hydrolysis of phosphodiester bonds of mononucleotides (Dhanajaya and D’Souza, 
2009). In the human body, these enzymes cause pathology at ruptured blood vessels, skin 
necrosis, deep tissue damage, osteomyelitis, and other significant consequences (Warrell, 2010). 
The inability of the snakebite wound to clot also increases the risk of secondary infection due to 
an open wound being exposed to the external environment. Due to many snake bites happening 
in the environment, oftentimes not close to civilization, many other pathogens tend to be present 
at the location that the bite occurred. Snakebite pathology can cause localized problems, 
including pain and edema or more systematic effects including chronic conditions (Slagboom et 
al., 2017). Symptoms vary based on numerous factors, including the snake species that caused 
the bite, the amount of venom injected, the location of the bite and how long it takes to get 
medical treatment.  
 
Materials  
 All protein reagents were purchased from BioRad Inc. (Hercules, CA, USA) and NuPage 
gels were obtained from Life Technologies, Inc (Grand Island, NY, USA). All other reagents 
were purchased from Sigma Biochemical Corp. (St. Louis, MO, USA). Size exclusion column, 
incubators, water bath, Agilent spectrophotometer and all other testing equipment were supplied 
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in the venom lab at the University of Northern Colorado by Dr. Stephen Mackessy.  
 All venoms were obtained from captive snakes maintained in the Animal Resource 
Facility in Ross Hall at UNC. Venoms were extracted manually as described previously 




 The first step to venom analysis is to collect the venom. This can be done from 
lyophilized venom previously collected or from fresh extraction of venom from the snake. In 
order to extract venom from a rattlesnake, precautions need to be practiced, included but not 
limited to not extracting the venom without Dr. Mackessy present (who is the only one extracting 
venoms), utilizing tools and safety techniques to obtaining the snake out of the cage, and clearing 
an area to make sure no one is in harm’s way. Once the snake is safely obtained, the snake is put 
under anesthesia using isoflurane in O2 in a small restraint box and once anesthetized, the snake 
is held by the back of the head to ensure no risk of a bite. Then, using small capillary tubes, an 
assistant places the tubes on each fang, being careful not to tear the delicate skin of the mouth, 
and the venom glands are gently massaged to release the fangs without hurting the snake. Once 
the venom is extracted, the amount is measured and recorded; additionally data on the individual 
snake is recorded.  
 
Size Exclusion Chromatography  
Size exclusion chromatography utilizes a column filled with porous beads that are made 
of polyacrylamide and the buffer solution. The beads have pores of varying sizes that help sort 
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macromolecules into different size classes as a sample moves through the column, and the small 
macromolecules are slowed by passing through most pores of the beads. Larger macromolecules 
emerge first and as time goes on, the smaller macromolecules come out. Size exclusion columns 
can be calibrated to determine the size of the proteins that fall within a certain size range. Once 
the size exclusion chromatography is finished running, the fractionated venom collected into 
tubes (termed fractions) is measured at 280 nm. The data is then plotted as fraction number vs. 
absorbance at 280 nm. Fractionated venom in the tubes is then sampled and diluted with a buffer 
specific to a particular enzyme assay.  
Crotalus oreganus lutosus size exclusion was done with venom from one male and one 
female snake; 100 µL from each were mixed with 800 µL of 25 nM HEPES, 100 nM NaCl, 5 
nM CaCl2 (pH 6.8) and run at flow rate of 6.0 mL/hr. Both snakes were extracted from the UNC 
collections of snakes (male was 2019-44 extraction and female was 2019-478). It was assumed 
to be 50 mg of proteins loaded, as rattlesnake venoms contain approximately 225-250 mg per mL 
protein.  
Crotalus oreganus oreganus size exclusion was a mixture of venom collected from a 
Lewiston, Idaho den site on April 17, 2019. 50.7 mg was dissolved in 750 µL 25 nM HEPES, 
100 nM NaCl, 5 nM CaCl2 (pH 6.8) buffer 12.6 mg of C. o. oreganus: 2019.228, DRS:346, ID: 
Nez, mixed with 12.718 mg of C. o. Oreganus: 2019.231, DRS: 349, ID: Nez, with 12.882mg C. 
o. Oreganus: 2019.224, DRS: 342, ID: Nez, with 12.448 mg of C. o. oreganus: 2019.226, 
DRS:346, ID:Nez.  
Crotalus oreganus oreganus size exclusion was obtained from an individual extracted on 
April 23rd 1984 from the Carrizo Plain, California. 21.2 mg of solid venom was mixed with 750 
µL of 25 nM HEPES, 100 nM NaCl, 5 nM CaCl2 (pH 6.8) buffer. 
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Crotalus oreganus helleri venom was a mixture of two individuals from Los Angeles 
Co., California in 2018. 60.1 mg of C. o. helleri (2018-208) was dissolved in 1500 µL of 25 mM 
HEPES, 100 mM NaCl, 5 mM CaCl2 (pH 6.8) buffer. 
Crotalus oreganus cerberus size exclusion used venom taken from individual 491 (2020-
172). 53.1 mg lyophilized venom was dissolved in 750 µL of 25 nM HEPES, 100 nM NaCl, 5 
nM CaCl2 (pH 6.8) buffer. 
Assays were then run on fractions to test for the presence of particular activities within 
the venom. This is done by taking a small aliquot of fractionated venom, combining it with a 
substrate specific for an enzyme that causes a reaction resulting in a color change that can be 
measured to obtain quantitative data. Each assay tests for a different enzyme (known to be most 
common in rattlesnake venoms), allowing for detection and quantification of different venom 
enzyme components that are known to cause major pathology for animals (including humans) 
when a bite from a rattlesnake occurs.  
 
Azocasein metalloproteinases assay (AZO) 
 Azocasein metalloproteinase assay followed a modified method of Aird and da Silva 
(1991). Metalloproteinases are larger macromolecules that resides in the first few peaks of 
venom that has gone through a size exclusion tube. The assay is done in 50 mM HEPES, 100 
mM NaCl (p.H. 8.0) buffer and azocasein protease substrate dissolved in the buffer at a 2.0 
mg/mL. 35 µL of column fraction with 365 µL of buffer and 35 µL substrate/buffer mix is used, 
terminated after 30 min with of 250 µL 0.5 trichloroacetic acid stop solution. Insoluble material 




Thrombin-like and kallikrein-like serine protease assay (THR and KAL) 
 Thrombin-like serine protease assay and kallikrein-like serine proteinase assays were 
based on modifications of Mackessy (1993). Both assays are done in the separate test, but both 
use 370 µL of the buffer of 50 mM HEPES with 100 mM NaCl at p.H. 8.0 with 5 uL of column 
fractions. However, kallikrein-like assay uses 50 µL of kal substrate where thrombin-like uses 50 
µL of THR substrate. All tubes were incubated at 37 C for 8 minutes total, 3 without substrate (to 
bring to temperature) and then 5.0 minutes after the substrate was added. Both reactions are 
terminated with 75 µL of 50% (v/v) acetic acid. The experiment is then read at 405 nm with two 
test blanks of 5 µL water instead of venom.  
 
L-amino acid oxidase assay (LAAO) 
  L-amino acid oxidase procedure was modified from Kishimoto and Takashahi 
(2001).  L-amino acid oxidase is a plate-based assay that combines 10 µL of venom from each 
fraction with 90 µL of a master mix. The Master mix contains 10X concentrations of L-
methionine, o-phenylenediamine and horseradish peroxidase in the borax buffer. In order to get 
each reagent to a 10x concentration they are mixed in solid form with a buffer. 5.0 mM L-
methionine is combined with borax at a 7.46 mg per 1 mL ration, 2.0 mM o-phenylenediamine is 
combined with buffer at 3.246 mg per 1 mL per 1mL ratio with buffer, and lastly horseradish 
peroxidase is combined with buffer at a o.316 per 1mL ratio to make a 100x stock solution. 
Horseradish peroxidase is then diluted in more buffers to make a 10x concentration that can now 
be used for the master mix. Per 1 mL, 700 µL of 50 mM borax buffer (pH 8.5) is combined with 
100 µL each of L-methionine, o-phenylenediamine and horseradish peroxidase.  After venom 
fractions and the master mix are combined, the procedure outlined to incubate the plate for 15 
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minutes at 37 C; however, all tests were terminated after 5 minutes due to high activity levels. 50 
µL 2.0 M sulfuric acid was added to terminate the reaction and the plate was read at 492nm with 
two blanks of 10uL of water instead of venom.  
 
Phospholipase A2 activity (PLA2) 
Phospholipase 𝐴2assay was modified from Holzer and Mackessy (1996). The procedure 
was modified to be a plate based assay. This was done by adding 165 µL of buffer that was made 
of 10mM tris-HCl, pH 8.0) with 10 nM Ca𝐶𝑙2and 100 nM NaCl, to 10 µL of venom. Then 25 µL 
of 3.0mM 4-nitro-3-(octanoyloxy) benzoic acid was added after being diluted in acetonitrile at a 
ratio of 0.96 mg per mL. The plate was incubated for 60 minutes at 37∘ 𝐶 and then read at 425nm 
frequency with two blanks of water instead of venom. Crotalus oreganus oreganus (present day) 
and C. o helleri venom fraction amount and substrate amount were increased (to 40 µL)  due to 
not seeing any significant data when procedures were run. 
 
Phosphodiesterase  
Phosphodiesterase activity was done based on Laskowski (1980) modification of Bjork 
(1963).  The biggest modification was it was a changed to be a plate based assay. 20 µL of 
venom from a fraction was mixed with 70 µL of 100 mM tris-HCl (pH of 9.0) with 10 mM 
Mg𝐶𝑙2. Then the substrate is made by 50 µL of 1.0 mM bis-p-nitrophenyl phosphate was 
dissolved in a buffer at a 0.362 mg per 1 mL concentration. Once substrate was added it was 
incubated at 37∘ 𝐶for 30 minutes and then immediately 125 µL of 100 nM NaOH with 20 nM 
diNa-EDTA to terminate the reaction. The plate is read at 400 nm absorbance with two blanks of 




The fractions need to be kept refrigerated in order to keep the venom in a working state. 
However, keeping around 200 test tubes of venom for each snake species takes up a lot of room 
and therefore once tests have been performed, the first 30 test tubes (ones with zero absorbance 
for initial absorbance test) can be discarded due to consisting of only buffer. After assays are 
completed, fractions making up specific peaks can be combined. Once combined, a gel can be 
run on a venom sample (compared to standards) to examine the amount of protein present in the 
venom and sizes of the protein for the whole venom compared to a different proteins in each size 
exclusion peak that has been combined. After a gel has been run, the gel needs to be stained and 
then excess stain needs to be taken up so the gel lines are viable.  Gels were not run on all 
species, only C. o. lutosus and C. o. oreganus. Once a gel is complete, the different peaks can be 
dialyzed using dialysis tubing to remove salts from the venom/buffer solutions. After 24 hr, the 
dialysis water was changed to maintain the salt concentration being higher in the venom solution 
compared to the water. Then the different combined peaks can be lyophilized, for smaller and 
easier storing that will keep the venom stable for later use on experiments. If the venom is 





Data analysis  
  
 
Figure 6. Size exclusion chromatogram of Crotalus oreganus lutosus venom. Approximately 50 
mg venom from 1 male and 1 female snake were mixed with 800 µL of 25 mM HEPES, 100 mM 





Figure 7. Size exclusion chromatogram of Crotalus oreganus oreganus venom. Venom was 
collected from snakes from a Lewiston, Idaho den site. 50.668 mg venom in 1.0 mL, with a flow 




Figure 8. Size exclusion chromatogram of Crotalus oreganus oreganus venom. Venom was 
collected  from an individual extracted on April 23rd 1984 in Carrizo plain California. 21.2 mg 




Figure 9. Size exclusion chromatogram of Crotalus oreganus helleri venom. The venom was a 
mixture of two individuals from Los Angeles California in 2018. 60.1 mg of C. o. helleri: 





Figure 10. Size exclusion chromatogram of Crotalus oreganus cerberus venom. Venom was 
taken from individual 491, from 2020.172. 53.14 mg solid venom mixed with 750 µL, with a 





Figure 11: Size exclusion chromatogram of Crotalus oreganus lutosus venom. Venom was taken 






Examining all five subspecies shows that LAAO and PDE enzymes are the largest size 
proteins in each venom. Both assays revealed them to be present in the first peak of activity after 
the size exclusion fractions were tested. Kallikrein-like activity and PLA2 were consistently seen 
to be in the second peak (or slightly before the second peak) in all individuals. The remaining 
assays showed up in multiple different places within the first two-three peaks; this includes 
thrombin-like as well as metalloproteinase activities. This is due to these enzymes having 
multiple sized proteins of these enzymes within the venom. After elution of enzymes (which are 
larger), the background absorbance remained at blank levels until the smaller peptides eluted late 
in the chromatogram. Levels of these peptides were variable between samples.  
 Size exclusion fraction readings varied greatly between species. Both individuals of C. o. 
oreganus and the C. o. lutosus species showed two large peaks within the first 40-100 fractions. 
Crotalus oreganus helleri displayed one large peak in the same range, as well as a smaller, less 
significant peak proceeding the large peak. Lastly, C. o. cerberus differed in size exclusion due 
to having three significant peaks between fraction numbers 40-100. After the beginning peaks, 
all fractions dropped to around zero until around fraction reading 120, where all individuals had 
low mass downstream peaks. These peaks ranged from one peak to multiple peaks. The height of 
the peaks ranged from the smallest 0.369 A280 nm (C. o. oreganus Carrizo) to 1.386 (C. o. helleri), 
followed closely by 1.36 in C. o. lutosus. Crotalus o. oreganus (Carrizo) had the lowest peak due 
to being the lowest total venom protein load.  
 Metalloproteinase activity showed variation from all other individuals due to having three 
significant peaks in C. o. lutosus within the first 100 fractions compared to all other individuals 
having one-two peaks in the remaining individuals. All peaks ranged from 0.377 in Helleri to 
0.89885 in Cerberus with all remaining individuals between those two. Both C. o.  oreganus 
34 
 
individuals, C. o. lutosus and C. o. cerberus had higher levels (0.614-0.899 absorbance) 
compared to C. o. helleri (0.377), indicating that C. o. helleri may not need metalloproteinase 
activity to be as high for prey along the southern California coast.  
All thrombin-like and kallikrein-like serine protease activity is most dominant in the 
second peak on the size exclusion reading with most species having higher levels of kallikrein 
compared to thrombin. Multiple individuals, including C. o. helleri and C. o. oreganus, had two 
peaks for thrombin within the first 40-100 fractions numbers. Kallikrein was seen to have higher 
activity than thrombin in all individuals except in C. o. lutosus, where the peaks were not in the 
same place, where both levels were exactly the same at a max peak at 0.649 absorbance. 
Crotalus oreganus helleri was seen to have the highest peak level of kallikrein at 0.963 
absorbance and was also seen to have the one of the lowest thrombin activity at 0.510 
absorbance. All individuals had between a 0.565-0.832 average absorbance when adding 
thrombin and kallikrein activity together divided by two. All samples that have higher levels of 
kallikrein tended to have lower levels of thrombin, with C. o. lutosus being in the middle with 
their activity being the same. This pattern shows the possibility that as one activity level 
increases (thrombin or kallikrein), the other activity seems to decrease. Kallikrein had the highest 
levels in C. o. helleri and C. o. cerberus as well as the two lowest levels of thrombin enzyme 
active. Both subspecies are located in the southern part of the United States, showing location 
may affect levels of serine protease activity.  
 Phospholipase A2 activity was low for all five samples run, with readings ranging from 
0.096-0.170 absorbance. In order to visualize activity on some of the graphs, readings were 
multiplied by 2 (shown in legend as X2). Crotalus oreganus cerberus was the only individual to 
show two peaks of PLA2 activity, compared to one peak in all the other four individuals. C. o. 
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cerberus also had the highest activity at 0.17. Though all individuals were close in range, reasons 
for some variation in age of the snakes, since PLA2 decreases with age.  
 All four species and all five individuals have high levels of LAAO activity; from the 
literature, LAAO is very common in many species and as size exclusion was run on each 
individual, all had an area of fractions with slight yellow tint, showing evidence of LAAO. 
Crotalus oreganus cerberus and C. o. oreganus (2019)  had slightly lower activity than all other 
individuals, with a peak at 1.058 (C. o. oreganus) and 1.047 (C. o. cerberus) compared to 1.225-
1.553 in the other individuals.  
 Phosphodiesterase activity was most significant in the first peak of each fraction in all 
individuals. The lowest activity was shown in C. o. oreganus, the rest of the individuals 
fluctuated significantly from 0.237 in the Carrizo C. o. oreganus compared to 1.0751 absorbance 
reading in C. o. cerberus. Crotalus. oreganus. cerberus and C. o. helleri showed the highest level 
of PDE compared to the other species and both C. o. cerberus and C. o. helleri tend to live closer 
to the southern United States than the rest of the species. The climate and prey selection in the 
more southern states may play a role in the increased level of PDE.  
 Data from the C. o. oreganus individuals taken in 2019 compared to the individuals in 
1984 showed significant differences. The snake in 1984 (Carrizo) showed two separate sized 
thrombin-like enzyme activity peaks and where the snake from 2019 did not. The 2019 snake, 
however, had high levels of thrombin at a peak of 0.746 compared to 0.583 as well as showed 
higher levels of kallikrein activity at 0.917 compared to the 1984 snake only peaking at 0.663. 
The 1984 individuals also showed significantly higher PDE levels peaking at 0.9985 absorbance 
compared to the 2019 individual only reaching a peak of 0.2365. However, the 2019 snake had 
larger LAAO activity with a peak spiking at 1.553 compared to 1.058 in the 1984 individuals. 
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Overall, AZO activity was similar in both species: 0.672 in the 1984 individual compared to 
0.614 in the 2019 snake. As well as PLA2 activity of 0.096 peak in the 1984 compared to 0.125 
in the 2019 snake. Snakes, like humans, are all unique but this significant amount of 
differentiation in their composition of venom shows genetic effects between these two species 
beyond just being individuals. The difference could be due to location, time of isolation or prey 
selection differing between the area the two individuals reside. To determine what caused the 
significant difference in the two species, future research would need to be done.  
 All five individuals displayed slightly different activity levels of each enzyme but all had 
activity for each assay run. This goes to show that natural selection, genetic drift, and other 
factors acting on random mutations have caused these subspecies to adapt to their new 
environment and cause their venom component to slightly change activity. There were notable 
differences in certain assay based on the year the venom was taken and some assays show the 
possibility of location playing a factor into enzyme active differences.  All subspecies give 
scientific proof of the similarities and difference between these subspecies venom components.  
Phospholipase A2 being in low quantities for these individuals is due to all test runs being run on 
adult rattlesnakes. Phospholipase A2 tend to decrease in activity as the juveniles are seen to have 
significantly greater amounts than adults. Crotalus oreganus lutosus showed the highest level of 
venom activity compared to all other individuals. In order to get a clearer comparison between 
the individuals of each subspecies, having the same age snakes would help to eliminate age bias 
in enzyme activity levels.  
 The frontier of snake venom in medicine and scientific research is just on the brink of 
explosion. The applications of venom in all fields is an exciting development that can change the 
way we treat life threatening diseases including but not limited to cancer, heart attacks and 
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strokes. The possibilities are still unknown for the application of these potentially life-saving 
components as the gap in turning venom into medicine is unstudied. Researchers need to see 
what the appropriate dose is to have enough venom to help but not too much that it hurts the 
patient. The future studies also need to address where in the body the venom proteins target 
wherein and if the researcher can use them to make medicine that helps though body systems 
without hurting the patient. Could it one day be injected to cure someone you love? 
Additional future research that can be done using the data above includes categorizing 
venom from isolating the proteins that are now in known locations. Once the venom is isolated, 
the components can be used in medical studies to help create new medications or the information 
on the levels of enzymes can be used for creating new anti-venoms. Determining patterns of 
levels of each enzyme in these subspecies also gives rise to information for determining 
evolutionary compounds. Seeing that different levels of activity that are present in different 
species can then be compared to diet preferences, location and other factors to see what aspects 
of natural selection are acting on mutation in venom to have driven these subspecies to have 
different levels of each enzyme.  
 
 
Potential sources of error 
 Differences in size exclusion column performance could also lead to errors. This was 
observed as diffuse peaks instead of well-defined peaks (not a major issue for this study). 
Inaccurate disruptions can happen through contamination or old matrix beads that are not 
collapsed and non-porous. Crotalus oreganus helleri venom was run on a different size column 
bead (fine, instead of medium), and the smaller beads caused the run to go longer, but it was 
accidentally stopped early. Because these later peaks did not pertain to the data used, the test was 
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not redone for C. o. helleri. Other sources of error are human errors including pipetting errors, 
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